[Quantitative-kinetic aspects of granulocytic resistance to infection in hematologic systemic diseases with reference to antineoplastic chemotherapy].
Sommer
S
S
III. Medizinische Klinik, Bezirkskrankenhauses H. Braun.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001853:Bone Marrow / Q000187:drug effects; D006098:Granulocytes / Q000187:drug effects*; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007938:Leukemia / Q000188:drug therapy* / Q000276:immunology; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000276:immunology; D007958:Leukocyte Count / Q000187:drug effects; D007962:Leukocytes / Q000187:drug effects*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000276:immunology; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000276:immunology
Quantitativ-kinetische Aspekte der granulozytären Infektabwehr bei hämatologischen Systemerkrankungen unter den Bedingungen der antineoplastischen Chemotherapie.